Dihydrexidine: Began Phase I testing of safety and efficacy in 10 patients, using several doses up to 10 mg/kg. Motor function will be measured with a commonly-

Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Product: Dihydrexidine, selective D1 receptor agonist Indication: Moderate to severe Parkinson's disease Status: Began Phase I testing of safe...